Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
What is Renvela?
The active ingredient inRenvela is sevelamer carbonate, a polymeric amine that binds
phosphate and is meant for oral administration. It was developed as a
pharmaceutical alternative to sevelamer hydrochloride
(Renagel). Sevelamer carbonate is an anion
exchange resin, with the same polymeric structure as sevelamer
hydrochloride, in which carbonate replaces chloride as the counterion.
While the counterions differ for the two salts, the polymer itself, the
active moiety involved in phosphate binding, is the same.
Renvela (sevelamer carbonate) is known chemically as poly(allylamine--N,N’-diallyl-1,3-diamino-2-hydroxypropane) carbonate salt. Sevelamer carbonate is hygroscopic, but insoluble in water. The structure is represented in .
Figure 1. Chemical Structure of Sevelamer Carbonate
a, b = number of primary amine groups a + b = 9c = number of crosslinking groups c = 1m = large number to indicate extended polymer network
What does Renvela look like?
What are the available doses of Renvela?
Tablets: 800 mg white oval, film-coated, compressed tablets
imprinted with “RENVELA 800”
What should I talk to my health care provider before I take Renvela?
How should I use Renvela?
Renvela (sevelamer carbonate) is indicated
for the control of serum phosphorus in patients with chronic kidney
disease (CKD) on dialysis.
Because of the rapid reaction with the hydrochloric acid in the stomach, the dosing of Renvela powder or tablet is anticipated to be similar to that of the sevelamer hydrochloride salt or tablet.
What interacts with Renvela?
Sorry No Records found
What are the warnings of Renvela?
Sorry No Records found
What are the precautions of Renvela?
Sorry No Records found
What are the side effects of Renvela?
Sorry No records found
What should I look out for while using Renvela?
Renvela is contraindicated in patients with bowel obstruction.
What might happen if I take too much Renvela?
Sevelamer hydrochloride, which contains the same active moiety as
sevelamer carbonate, has been given to normal healthy volunteers in
doses of up to 14 grams per day for eight days with no adverse effects.
In CKD patients on dialysis, the maximum dose studied was 14 grams of
sevelamer carbonate and 13 grams of sevelamer hydrochloride. There are
no reports of overdosage with sevelamer carbonate or sevelamer
hydrochloride in patients. Since sevelamer is not absorbed, the risk of
systemic toxicity is low.
How should I store and handle Renvela?
Store at 25°C (77° F); excursions permitted to 15-30 °C (59-86°F) [see USP Controlled Room Temperature].Tablets: Renvela 800 mg Tablets are supplied as white oval, film-coated, compressed tablets, imprinted with “RENVELA 800”, containing 800 mg of sevelamer carbonate on an anhydrous basis, microcrystalline cellulose, hypromellose, diacetylated monoglycerides, sodium chloride, and zinc stearate.1 Box Unit Dose of 30 ct 800 mg Tablets (NDC 0179-0043-70)Storage: Tablets: Renvela 800 mg Tablets are supplied as white oval, film-coated, compressed tablets, imprinted with “RENVELA 800”, containing 800 mg of sevelamer carbonate on an anhydrous basis, microcrystalline cellulose, hypromellose, diacetylated monoglycerides, sodium chloride, and zinc stearate.1 Box Unit Dose of 30 ct 800 mg Tablets (NDC 0179-0043-70)Storage: Tablets: Renvela 800 mg Tablets are supplied as white oval, film-coated, compressed tablets, imprinted with “RENVELA 800”, containing 800 mg of sevelamer carbonate on an anhydrous basis, microcrystalline cellulose, hypromellose, diacetylated monoglycerides, sodium chloride, and zinc stearate.1 Box Unit Dose of 30 ct 800 mg Tablets (NDC 0179-0043-70)Storage:
Chemical StructureNo Image found
Renvela contains sevelamer carbonate, a non-absorbed
phosphate binding crosslinked polymer, free of metal and
calcium. It contains multiple amines separated by one carbon
from the polymer backbone. These amines exist in a protonated
form in the intestine and interact with phosphate molecules
through ionic and hydrogen bonding. By binding phosphate in
the gastrointestinal tract and decreasing absorption,
sevelamer carbonate lowers the phosphate concentration in the
serum (serum phosphorus).
Non-Clinical ToxicologyRenvela is contraindicated in patients with bowel obstruction.
When given concurrently the following drugs may interact with thiazide diuretics.
Alcohol, barbiturates, or narcotics
Other antihypertensive drugs
Cholestyramine and colestipol resins
Pressor amines (e.g., norepinephrine)
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)
Non-steroidal Anti-inflammatory Drugs
The safety of Renvela has not been established in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery. Uncommon cases of bowel obstruction and perforation have been reported.
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
ProfessionalClonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
InteractionsA total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).